Welcome!

News Feed Item

Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, March 18, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Cell  Therapeutics,  Inc.  Analyst  Notes

On March 3, 2014, Cell Therapeutics, Inc. (CTI) announced the initiation of a Phase 3 clinical trial, PERSIST-2, evaluating pacritinib. Pacritinib is a novel investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). "With the initiation of the PERSIST-2 trial, we believe that the registration program for pacritinib is on track for a potential NDA submission in the latter part of 2015," said James A. Bianco, MD, President and CEO of CTI. "We have seen meaningful clinical benefits and good tolerability with pacritinib in myelofibrosis patients in Phase 2 trials without apparent drug-related thrombocytopenia or anemia. As such, we have had strong interest in site participation for this trial and will work diligently to activate these sites over the next several months." The trial is expected to enroll up to 300 patients in North America, Europe, Australia and New Zealand within 12 to 14 months. The full analyst notes on Cell Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/CTIC/report.pdf

Intrexon  Corporation  Analyst  Notes

On March 7, 2014, Intrexon Corp. (Intrexon) announced that it has completed the acquisition of Medistem, Inc., a pioneer in the development of Endometrial Regenerative Cells. Under the terms of the agreement, Medistem stockholders will receive in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of Intrexon common stock, or approximately 0.03920 shares. This is based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing, subject to adjustment pursuant to the terms of the merger agreement. The full analyst notes on Intrexon Corporation are available to download free of charge at:

http://www.AnalystsReview.com/03182014/XON/report.pdf

Chimerix,  Inc.  Analyst  Notes

On March 7, 2014, Chimerix Inc. (Chimerix) reported its Q4 2013 and full-year 2013 financial results. For the quarter, the Company reported a net loss of $8.2 million or $0.31 per basic and diluted share,compared to a net loss of $4.3 million or $3.90 per basic and diluted share in Q4 2012. Revenues totaled $879,000, compared to $3.6 million in Q4 2012. For full-year 2013, net loss was $36.4 million or $3.65 per basic and diluted share, compared to net loss of $4.4 million or $5.75 per basic and diluted share in 2012. Revenues were $4.4 million, compared to $33.7 million in 2012. The decrease in revenues were attributable to a decrease in reimbursable expenses associated with Chimerix's ongoing contract with BARDA in 2013, and the receipt of an upfront license payment related to Chimerix's collaboration and license arrangement with Merck in 2012. The full analyst notes on Chimerix, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/CMRX/report.pdf

Receptos,  Inc.  Analyst  Notes

On March 5, 2014, Receptos, Inc. (Receptos) reported its Q4 2013 and full-year 2013 (period ended December 31, 2013) financial results. For the quarter, the Company reported net loss of $15.2 million, or $0.86 per common share, compared to a net loss of $4.5 million, or $3.08 per common share, in Q4 2012. Total revenues were $773,000, compared to $3.8 million in Q4 2012. Revenue during these periods consisted primarily of amortization of up-front fees and milestone payments, and development funding received from our collaborative arrangements. Fiscal year 2013 net loss was as $50.4 million, or $4.23 per common share, compared to a net loss of $17.7 million, or $13.73 per common share, in 2012. Total revenues were $4.6 million compared to $8.6 million in 2012. The full analyst notes on Receptos, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/RCPT/report.pdf

Revance  Therapeutics,  Inc.  Analyst  Notes

On March 12, 2014, Revance Therapeutics, Inc. (Revance) announced the schedule of its earnings release and conference call. The Company will report its Q4 2013 and full-year 2013 financial results on March 26, 2014, Wednesday, after the close of market. The Company's management will also host a conference call and live internet webcast on the same day at 1:30 p.m. PT or 4:30 p.m. ET to discuss the results as well as provide business updates. The webcast will be available in the Investor Relations section on the Company's website for 30 days following the completion of the call. The full analyst notes on Revance Therapeutics, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03182014/RVNC/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

=============

EDITOR  NOTES:

  • This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  • Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  • This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  • If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
  • For  any  urgent  concerns  or  inquiries, please contact us at compliance [at] AnalystsReview.com.
  • Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE  PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT  FINANCIAL  ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO  WARRANTY  OR  LIABILITY  ASSUMED

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AnalystsReview.com

SOURCE Analysts Review

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
We all know that end users experience the internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices - not doing so will be a path to eventual ...
DXWorldEXPO LLC announced today that ICC-USA, a computer systems integrator and server manufacturing company focused on developing products and product appliances, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. DXWordEXPO New York 2018, colocated with CloudEXPO New York 2018 will be held November 11-13, 2018, in New York City. ICC is a computer systems integrator and server manufacturing company focused on developing products and product appliances to meet a wide range of ...
Sanjeev Sharma Joins November 11-13, 2018 @DevOpsSummit at @CloudEXPO New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
Dion Hinchcliffe is an internationally recognized digital expert, bestselling book author, frequent keynote speaker, analyst, futurist, and transformation expert based in Washington, DC. He is currently Chief Strategy Officer at the industry-leading digital strategy and online community solutions firm, 7Summits.
In an era of historic innovation fueled by unprecedented access to data and technology, the low cost and risk of entering new markets has leveled the playing field for business. Today, any ambitious innovator can easily introduce a new application or product that can reinvent business models and transform the client experience. In their Day 2 Keynote at 19th Cloud Expo, Mercer Rowe, IBM Vice President of Strategic Alliances, and Raejeanne Skillern, Intel Vice President of Data Center Group and ...
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
HyperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let's say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it...
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, led attendees through the exciting evolution of the cloud. He looked at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering m...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
From 2013, NTT Communications has been providing cPaaS service, SkyWay. Its customer’s expectations for leveraging WebRTC technology are not only typical real-time communication use cases such as Web conference, remote education, but also IoT use cases such as remote camera monitoring, smart-glass, and robotic. Because of this, NTT Communications has numerous IoT business use-cases that its customers are developing on top of PaaS. WebRTC will lead IoT businesses to be more innovative and address...